Immix Biopharma - KOL event: Glimmer of hope for ALA patients
Immix hosted a key opinion leader (KOL) event highlighting the long-term potential for NXC-201, the company’s B-cell maturation antigen (BCMA)...
392 Views
Immix Biopharma - CAR-T trial moves to US with outpatient potential
The FDA has accepted Immix’s Investigational New Drug (IND) application for lead CAR-T asset NXC-201. In our view, this decision from the FDA...
248 Views
Immix Biopharma - A quarter of progress for both lead assets
Throughout Q323, Immix shared encouraging updates for the clinical development of lead CAR-T asset NXC-201, including the announcement of orphan...
403 Views
Immix Biopharma - A step toward delivering a practical CAR-T option
Immix has announced encouraging updated clinical data for NXC-201, a B cell maturation antigen (BCMA) targeting CAR-T therapy, which is being...
276 Views
Immix Biopharma - NXC-201 gains orphan drug designation in ALA
Immix has announced that the FDA has granted orphan drug designation (ODD) to CAR-T asset NXC-201 for amyloid light chain amyloidosis (ALA). This...
394 Views